Treat-to-target in systemic lupus erythematosus: advancing towards its implementation
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treat-to-target in systemic lupus erythematosus: advancing towards its implementation
Authors
Keywords
-
Journal
Nature Reviews Rheumatology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-17
DOI
10.1038/s41584-021-00739-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Remission in SLE—do DORIS criteria match the treating physician’s judgment? A cross sectional study to assess reasons for discordance
- (2021) Johanna Mucke et al. RHEUMATOLOGY
- OP0106 THE ASSOCIATIONS BETWEEN BARIATRIC SURGERY AND HIP OR KNEE ARTHROPLASTY, AND HIP OR KNEE OSTEOARTHRITIS: A COHORT STUDY FROM SWEDISH NATIONWIDE HEALTHCARE REGISTRIES
- (2021) T. Burkard et al. ANNALS OF THE RHEUMATIC DISEASES
- Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort
- (2021) Yanjie Hao et al. CLINICAL RHEUMATOLOGY
- Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study
- (2021) Tomas Walhelm et al. Frontiers in Immunology
- 2021 DORIS definition of remission in SLE: final recommendations from an international task force
- (2021) Ronald F van Vollenhoven et al. Lupus Science & Medicine
- Treatment strategies are more important than drugs in the management of rheumatoid arthritis
- (2020) Alexandros A. Drosos et al. CLINICAL RHEUMATOLOGY
- Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study
- (2020) Eric F Morand et al. RHEUMATOLOGY
- 2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis
- (2020) Antonis Fanouriakis et al. ANNALS OF THE RHEUMATIC DISEASES
- Response to: ‘Presence of anti-phospholipid antibodies in COVID-19: a case series study’ by Amezcua-Guerra et al
- (2020) Alexis Mathian et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results
- (2020) Tineke Kraaij et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- An Update on the Diagnosis and Management of Lupus Nephritis
- (2020) Myrto Kostopoulou et al. Current Rheumatology Reports
- Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New
- (2020) Fabio Basta et al. Rheumatology and Therapy
- Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus
- (2019) Shereen Oon et al. ANNALS OF THE RHEUMATIC DISEASES
- 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
- (2019) Antonis Fanouriakis et al. ANNALS OF THE RHEUMATIC DISEASES
- Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
- (2019) Ruediger Mueller et al. Journal of Clinical Medicine
- Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
- (2019) Ioannis Parodis et al. RHEUMATOLOGY
- Low Disease Activity State/Remission Predicts a Better Health‐Related Quality of Life in Systemic Lupus Erythematosus Patients
- (2019) Manuel F. Ugarte‐Gil et al. ARTHRITIS CARE & RESEARCH
- Remission and low disease activity state prevent hospitalizations in systemic lupus erythematosus patients
- (2019) C Reátegui-Sokolova et al. LUPUS
- Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African‐American Ethnicity
- (2019) Hakan Babaoglu et al. ARTHRITIS CARE & RESEARCH
- Treat to Target in Rheumatology
- (2019) Josef S. Smolen RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Treat to Target in Systemic Lupus Erythematosus
- (2019) Martin Aringer et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Trial of Anifrolumab in Active Systemic Lupus Erythematosus
- (2019) Eric F. Morand et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:post-hocanalysis of the Phase IIb MUSE trial of anifrolumab
- (2018) Eric F Morand et al. ANNALS OF THE RHEUMATIC DISEASES
- Renal Remission Status and Longterm Renal Survival in Patients with Lupus Nephritis: A Retrospective Cohort Analysis
- (2018) Julie E. Davidson et al. JOURNAL OF RHEUMATOLOGY
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2018) Daniel J Wallace et al. LANCET
- Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus
- (2018) Tomonori Ishii et al. Modern Rheumatology
- Recent developments in biologic therapies for the treatment of patients with systemic lupus erythematosus
- (2018) Pedro L Carreira et al. RHEUMATOLOGY
- Benefits and Sustainability of a Learning Collaborative for Implementation of Treat to Target in Rheumatoid Arthritis: Results of the TRACTION Trial Phase II
- (2018) Daniel H. Solomon et al. ARTHRITIS CARE & RESEARCH
- Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
- (2018) A. Doria et al. Arthritis & Rheumatology
- Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort
- (2018) Michelle Petri et al. Arthritis & Rheumatology
- Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus
- (2018) Joan T. Merrill et al. Arthritis & Rheumatology
- Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
- (2018) Joan T Merrill et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
- (2018) Ronald F van Vollenhoven et al. LANCET
- A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis
- (2018) Hong Wang Archives of Rheumatology
- A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis
- (2018) Brad H. Rovin et al. KIDNEY INTERNATIONAL
- New therapeutic strategies in systemic lupus erythematosus management
- (2018) Mariele Gatto et al. Nature Reviews Rheumatology
- The relationship between remission and health-related quality of life in a cohort of SLE patients
- (2018) Michel W P Tsang-A-Sjoe et al. RHEUMATOLOGY
- Implementation of treat-to-target principles in the management of systemic lupus erythematosus
- (2017) E Zirkzee et al. LUPUS
- Severe infections in patients with lupus nephritis treated with immunosuppressants: A retrospective cohort study
- (2017) Cynthia C Lim et al. NEPHROLOGY
- Janus kinase inhibitors clear to land
- (2017) Martin Aringer RHEUMATOLOGY
- Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study
- (2017) Vera Golder et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials
- (2017) Megan E. B. Clowse et al. Arthritis & Rheumatology
- Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
- (2017) Richard Furie et al. Arthritis & Rheumatology
- Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
- (2017) William Stohl et al. Arthritis & Rheumatology
- Remission in systemic lupus erythematosus: durable remission is rare
- (2016) Theresa R Wilhelm et al. ANNALS OF THE RHEUMATIC DISEASES
- The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients
- (2016) Margherita Zen et al. ANNALS OF THE RHEUMATIC DISEASES
- Treat-to-target (T2T) recommendations for gout
- (2016) U Kiltz et al. ANNALS OF THE RHEUMATIC DISEASES
- A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
- (2016) Ronald van Vollenhoven et al. ANNALS OF THE RHEUMATIC DISEASES
- Abatacept for the treatment of systemic lupus erythematosus
- (2016) Victor R. Pimentel-Quiroz et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus
- (2016) Michel W. P. Tsang-A-Sjoe et al. RHEUMATOLOGY
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis
- (2016) Brad H. Rovin et al. Arthritis & Rheumatology
- Prolonged remission in Caucasian patients with SLE: prevalence and outcomes
- (2015) Margherita Zen et al. ANNALS OF THE RHEUMATIC DISEASES
- Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point
- (2015) Daniel Aletaha et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
- (2015) J T Merrill et al. ANNALS OF THE RHEUMATIC DISEASES
- Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
- (2015) Kate Franklyn et al. ANNALS OF THE RHEUMATIC DISEASES
- Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update
- (2015) Michaela A Stoffer et al. ANNALS OF THE RHEUMATIC DISEASES
- Systemic lupus erythematosus: review of synthetic drugs
- (2015) MWP Tsang-A-Sjoe et al. EXPERT OPINION ON PHARMACOTHERAPY
- The frequency and outcome of lupus nephritis: results from an international inception cohort study
- (2015) John G. Hanly et al. RHEUMATOLOGY
- Predictors of Long-Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro-Lupus Nephritis Cohort
- (2015) Maria Dall'Era et al. Arthritis & Rheumatology
- Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
- (2014) Ian N Bruce et al. ANNALS OF THE RHEUMATIC DISEASES
- Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
- (2014) Ronald F van Vollenhoven et al. ANNALS OF THE RHEUMATIC DISEASES
- The role of tyrosine kinases in systemic lupus erythematosus and their potential as therapeutic targets
- (2014) Wen-Hai Shao et al. Expert Review of Clinical Immunology
- The need to define treatment goals for systemic lupus erythematosus
- (2014) Kate Franklyn et al. Nature Reviews Rheumatology
- Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
- (2013) Marie B Condon et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study
- (2013) Eduardo F. Mysler et al. ARTHRITIS AND RHEUMATISM
- Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve-Month, Randomized, Double-Blind Study
- (2013) Richard Furie et al. Arthritis & Rheumatology
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
- (2012) Brad H. Rovin et al. ARTHRITIS AND RHEUMATISM
- Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial
- (2012) Ellen M Ginzler et al. ARTHRITIS RESEARCH & THERAPY
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
- (2011) Richard Furie et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
- (2011) Sandra V Navarra et al. LANCET
- Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis
- (2011) M Zeher et al. LUPUS
- 'Treat to target': moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis
- (2010) D. Atar et al. ANNALS OF THE RHEUMATIC DISEASES
- The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial
- (2010) J. T. Merrill et al. ARTHRITIS AND RHEUMATISM
- Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study
- (2010) Gabor G. Illei et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
- (2009) Joan T. Merrill et al. ARTHRITIS AND RHEUMATISM
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started